Qurient Co., Ltd. (KOSDAQ:115180)

Market Cap	1.03T +183.6%
Revenue (ttm)	7.00B -22.1%
Net Income	-31.77B
EPS	-895.03
Shares Out	40.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,952
Open	24,350
Previous Close	26,350
Day's Range	23,350 - 25,250
52-Week Range	9,520 - 62,900
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2025, Qurient's revenue was 6.98 billion, a decrease of -23.94% compared to the previous year's 9.18 billion. Losses were -30.12 billion, 24.9% more than in 2024.